Impact of biologic induction dose and concomitant drugs on anti‐drug antibody formation in a pediatric IBD cohort with high Hispanic representation
High-dose IFX may obviate the need for CIT in ADA prevention in pediatric IBD. UC patients may benefit more from CIT than CD patients. Disparities in treatment timing and medication use among Hispanic UC patients highlight the need for further investigation.
Authors
- Roy Nattiv
- Robert K. Tran (ORCID: https://orcid.org/0000-0002-4935-6847)
- Jenilee Pohle
- Kenneth J. Grant
Institutions
- University of California, Irvine (US)
- Miller Children's & Women's Hospital (US)
Publication Details
- Journal
- JPGN Reports
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1002/jpr3.70036
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00